![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
The Advanced Therapies Commercialisation Congress is a collaborative, multi-stakeholder meeting for exchanging views and exploring business approaches for the evolving ATMP segment.
This congress convenes industry executives, public policy makers, academia and other professionals in the advanced therapies community to address the key barriers and exciting opportunities on the journey to commercialisation of these innovative technologies. Download the agenda at www.cbinet.com/advancedtherapies.
Key Issues to be addressed: www.cbinet.com/advancedtherapies
- Hear case studies from industry pioneers
- Review recent and upcoming events in the ATMP space
- Anaylse the Glybera case as the first GT approved in the western world
- Weigh the pros and cons of EU-accelerated clinical development and market access pathways
- Examine the drivers for outcomes-based innovative contracts
- Draw insights from ATMPs that have been commercialisied to date to inform future market access strategies
- Consider the technologies and infrastructure needed in the future to mainstream these products
- Learn about recent pricing and reimbursement strategies for cell and gene therapies in the EU and US
- Deliberate over real-world challenges and approaches to defining and demonstrating therapy value
Learn more at www.cbinet.com/advancedtherapies
